Glatiramer acetate - Lanco Biosciences

Drug Profile

Glatiramer acetate - Lanco Biosciences

Alternative Names: copolymer-1 - Lanco Biosciences; LBS-102

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator Lanco Biosciences
  • Class Peptides; Polymers
  • Mechanism of Action Immunomodulators; MHC class II gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Preclinical Multiple sclerosis

Most Recent Events

  • 12 Sep 2016 Chemical structure information added
  • 12 Aug 2016 Preclinical trials in Multiple sclerosis in USA (Transdermal)
  • 12 Aug 2016 Glatiramer acetate - Lanco Biosciences is available for licensing as of 12 Aug 2016. https://lancobio.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top